IL-33: a Janus cytokine

Liew, F.Y. (2012) IL-33: a Janus cytokine. Annals of the Rheumatic Diseases, 71(Sup. 2), i101-i104. (doi: 10.1136/annrheumdis-2011-200589)

Full text not currently available from Enlighten.

Publisher's URL:


Interleukin (IL) 33, a member of the IL-1 family, is the ligand of ST2 that is expressed mainly on activated Th2 cells and mast cells. IL-33 can skew a predominantly Th1 cell population to a mainly Th2 cells phenotype in vivo. IL-33 messenger RNA is expressed early during infection of the intestinal-dwelling nematode Trichuris muris in mice. IL-33 treatment enhances resistance to Trichuris infection. IL-33 also effectively attenuates sepsis by mobilising the innate cells, neutrophils, to the site of infection, helping to clear the pathogens. Thus, IL-33 may be evolutionally preserved for the host defence against infections. IL-33 can reduce an ongoing atherosclerosis in ApoE−/− mice and attenuate adipocytes mainly by inducing the production of type II cytokines. In contrast, IL-33 can also exacerbate allergy and the inflammation in collagen-induced or serum-induced arthritis. Hence, IL-33 is a double-edged sword, and targeting IL-33 should be approached with caution.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Liew, Prof Foo
Authors: Liew, F.Y.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Annals of the Rheumatic Diseases
Publisher:B M J Group
ISSN (Online):1468-2060
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
486461The role of IL-35 in infection and inflammationFoo LiewMedical Research Council (MRC)G0801198III -IMMUNOLOGY